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Abstract: Glaucoma and age-related macular degeneration are leading causes of irreversible blindness
worldwide with significant health and societal burdens. To date, no clinical cures are available and
treatments target only the manageable symptoms and risk factors (but do not remediate the underlying
pathology of the disease). Both diseases are neurodegenerative in their pathology of the retina and
as such many of the events that trigger cell dysfunction, degeneration, and eventual loss are due to
mitochondrial dysfunction, inflammation, and oxidative stress. Here, we critically review how a
decreased bioavailability of nicotinamide adenine dinucleotide (NAD; a crucial metabolite in healthy
and disease states) may underpin many of these aberrant mechanisms. We propose how exogenous
sources of NAD may become a therapeutic standard for the treatment of these conditions.
Keywords: nicotinamide adenine dinucleotide; glaucoma; age-related macular degeneration;
mitochondria; retina; optic nerve; retinal pigment epithelium
1. Introduction
Glaucoma and age-related macular degeneration (AMD) account for the majority of irreversible
blindness cases in the elderly [1,2]. These diseases share common pathophysiological processes, such as
oxidative stress, inflammation, and mitochondrial dysfunction. Glaucoma is characterized by the
progressive dysfunction and loss of retinal ganglion cells (RGCs; the output neuron of the retina),
thinning of the retinal nerve fiber layer (RNFL; the axons of RGCs), cupping of the optic disc and
optic nerve degeneration resulting in irreversible blindness [3]. Glaucoma can be divided into two
main categories, open-angle and angle-closure, depending on the anatomy of the anterior chamber
angle. Despite morphological variations and the pathological progression rate, both are associated
with increased intraocular pressure (IOP or ocular hypertension), the only current clinical therapeutic
target [4]. While elevated IOP is the principal therapeutic target, glaucomatous damage can arise in eyes
with IOPs in the normal range (also referred to as normal tension glaucoma, NTG) [5], although there
is evidence that IOP lowering strategies have therapeutic benefit in some of these cases [6].
In AMD, the causative pathology lies in the outer retinal layers characterized by photoreceptor and
retinal pigment epithelium (RPE) degeneration resulting in central vision loss [7]. One of the hallmarks
of AMD is drusen, collections of degeneration material lying at the level of the RPE/Bruch’s membrane
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interface [8]. These deposits under the macula are often used to identify the stage of the pathology.
AMD is clinically classified based on the presence of exudate as either the dry (atrophic) form or the wet
(neovascular) form [9]. Dry AMD, which is the most frequent, displays a slow progressive dysfunction
of RPE, photoreceptor loss, and retinal degeneration, while wet AMD, which is more aggressive and
has a faster progression, presents as choroidal neovascularization with either intraretinal or subretinal
leakage, hemorrhage, and RPE detachment [10,11]. There has been intense interest in the development
of more effective therapies to arrest the progression of AMD. The U.S. National Library of Medicine
currently lists that 272 out of 1716 AMD clinical trials are still active worldwide [12]. There is some
evidence that dietary supplementation or nutraceuticals can be beneficial in some types of AMD.
The Age-Related Disease Study (AREDS) demonstrated that a daily supplementation of an antioxidant
cocktail (e.g., vitamin C, vitamin E, zinc and cupric oxide, and β-carotene) to be effective in delaying the
progression of intermediate to advanced AMD. In a second study, AREDS2, β-carotene was substituted
with lutein due to the increase incidence of lung cancer related to that supplement administration in
current or former smokers [13]. The most effective treatment, albeit exclusively used for wet AMD,
has come with the use of monoclonal antibodies which are injected intravitreally to arrest the effect
of vascular endothelial growth factor (VEGF) in the development of subretinal neovascularization.
Although anti-VEGF is the current mainstay approved treatment, it is not able to reverse vision already
lost and to impede recurrences of CNV [14].
Both glaucoma and AMD share many common underling mechanisms. In this context,
nicotinamide adenine dinucleotide (NAD+) has received considerable interest as a neuroprotective
agent. NAD+ is a key molecule in healthy neurons and plays central role in cellular bioenergetics [15].
Its age-related depletion affects the biological coping mechanisms associated with inflammation,
oxidative stress, and accumulation of damaged molecules [16]. All these alterations are intrinsically
linked to retinal degenerative pathologies, such as glaucoma and AMD, and with compelling evidence
that NAD+ supplementation would be a promising intervention in these diseases [17], alone or
possibly in combination with other nutraceutical agents such as saffron [18,19] and zeaxanthin [20,21],
or pyruvate [22], which together provide neuroprotection by targeting multiple disease mechanisms.
This review focuses on the shared pathophysiological mechanisms of glaucoma and AMD and the
potential role that NAD+ may play in their mitigation.
2. Nicotinamide Adenine Dinucleotide
2.1. NAD Biosynthetic Pathways
NAD+ was first reported in 1906 as a product of yeast fermentation [23,24]. The potential
importance of NAD+ was revealed in 1937 when Joseph Goldberger identified that deficiency of
vitamin B, the common name of nicotinic acid and a precursor of NAD+, as the cause for pellagra [25].
Diets high in corn and deficient in animal protein sources were implicated in the disease since animal
protein is a major source of the essential amino acid tryptophan which is the only source for the de novo
biosynthesis of NAD+. NAD+ is the last enzymatic product of three important biosynthetic pathways in
the mammalian metabolism, the kynurenine (de novo), Preiss–Handler (from nicotinic acid), and salvage
(recycling NAD+ from nicotinamide) pathways. The common limiting step for NAD+ synthesis is
the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT) expressed as three protein
isoforms (NMNAT1, NMNAT2, and NMNAT3) with differing cellular localizations [26]. These three
protein variants have differential effects on cellular bioenergetics depending on the paralogue that is
involved in the catalysis of NAD+ [27]. NMNAT1 and NMNAT3 are ubiquitously expressed, but in
mammalian systems NMNAT1 is predominantly nuclear while NMNAT3 is mitochondrial. NMNAT2
localizes to the Golgi and cytosolic compartments and localized exclusively to neurons and hair
follicles [28]. In neurons, NMNAT2 plays a pivotal role in axon development and survival [29–31] and
its depletion can trigger Wallerian degeneration [32,33]. While the role of NAD+ in balancing cellular
homeostasis is evolutionally conserved [34], only three pathways that lead to NAD+ synthesis have
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been described (in mammalian cells, the core focus of this review) [35]. De novo NAD+ synthesis
initiates with the amino acid tryptophan (TRP) which is enzymatically degraded into kynurenine,
which after a series of reactions leads to NAD+ [36]. The Preiss-Handler and the salvage pathways
are the other sources of NAD+ [37–39]. The Preiss-Handler pathway comprises three enzymatic steps
that start with the phosphoribosylation of nicotinic acid and end with the amidation of nicotinic acid
adenine dinucleotide into NAD+ [40]. The salvage pathway is responsible for 80% of cellular NAD+
production through the action of nicotinamide phosphoribosyltransferase (NAMPT) and NMNAT 1,
which convert nicotinamide (NAM), or other NAD+ precursors such as nicotinamide riboside (NR),
into NAD+ [39,41]. NAMPT first converts transforms NAM into nicotinamide mononucleotide (NMN)
which is then aminated to NAD+ by NMNATs. The salvage pathway maintains the cellular NAD+
pools by recycling NAD+ from multiple sources. Once consumed, NAD+ is reinserted in the pathway
as NAM for subsequent enzymatic modfication and recycling to NAD+ [42–44]. Besides NMNATs,
three other class of molecules are worth mentioning: sirtuins (SIRTs), poly(ADP-ribose) polymerases
(PARPs), and CD38. These enzymes require NAD+ as a substrate for their activities thus directly
contributing to the delicate balance of NAD+ homeostasis [45]. SIRTs are involved in neuroprotection,
neuronal development, survival, cell senescence, mitochondrial homeostasis, and cellular turnover.
PARPs are crucial for DNA repair mechanisms and cellular stress responses [46]. CD38 is involved in
aging, inflammation, and in some circumstances degrades NAD+ precursors [47].
2.2. NAD+ in Aging and Neurodegeneration
Biologically, physiological aging is a highly regulated process in which damage is taken into
account but mitigated by compensating cellular processes. Conversely, uncontrolled aging, senescence,
and degeneration irrevocably alter several cellular functions. Compelling evidence has identified a
link between NAD+ and aging, and, although cellular NAD+ decline with age is normal, disruptions
in NAD+ homeostasis are associated with aging pathologies as well as age-related diseases. As a
proof of concept, many experiments conducted using model systems such as yeast, C. elegans,
D. melanogaster, mice, and human cells have demonstrated that NAD+ replenishment can extend life
span and health span [48–51]. Furthermore, the connection between central nervous system (CNS)
impairment and NAD+ deficiency has been documented since the discovery of pellagra, in which
neuro-dysfunction is one of the early manifestations of the disease [52]. This physiological link has
been clarified further by evidence that NAD+ is one of the key molecules involved in neuroprotection,
neuroinflammation, mitochondrial function, and adaptive responses to oxidative stress [15,26]. NAD+
pools during aging are deeply affected by PARPs, CD38 increased activity, and mitochondria SIRT3 loss
of function [53]. Mitochondrial dysfunction due to lowered NAD+ bioavailability is also a common
feature of Alzheimer’s disease (AD), Parkinson’s disease (PD), glaucoma, and AMD [54,55].
Mitochondria are not only the cell’s energy source but also regulate several cellular metabolic
responses such as oxidative stress and calcium homeostasis, take part in the unfolded protein
response (UPRmt) [56], and regulate apoptosis [57]. As such, their dysfunction or insufficiency
dramatically affects cellular health and homeostasis [58]. All these functions are closely related to NAD+
availability. The efficient mitochondrial ATP production is mediated by oxidative phosphorylation
system (OXPHOS), which is composed by multimeric complexes (Complexes I–IV), coenzyme Q,
cytochrome C, and the F0-F1 ATPase (Complex V) [59]. Mitochondrial DNA (mtDNA) encodes for
13 structural subunits of Complexes I, III, IV, and V while the nuclear DNA (nDNA) for the further
genes required for mtDNA maintenance, replication, transcription, translation, post-translational
modification, transport, and assembly [60]. The probability of deficits in these pathways dramatically
increases with age, and if damaged mitochondria are not cleared the remaining organelles cannot
effectively compensate for the loss of capacity in the OXPHOS pathway [61]. This results in an excess
ROS production due to the electron leakage along the respiratory chain [62]. The associated oxidative
stress triggers secondary downstream deficiencies manifest as an NAD+ imbalance or alteration in
Ca2+ homeostasis [63]. Mitochondrial Ca2+ accumulation enables the opening of the mitochondrial
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permeability transition pore (MPTP), which induces the release of pro-apoptotic molecules such
cytochrome C and caspases that activate the intrinsic apoptotic pathway [64]. The adverse oxidative
state that results from mitochondrial dysfunction can provoke a vicious cycle that can drive continued
damage due to increased ROS production triggering an extended inflammatory reaction that intensify
the damage. ROS acts as signaling molecules in several intracellular signaling pathways that help
to maintain a physiological redox state when there is a balanced cellular crosstalk. When this
communication is dysregulated by oxidative stress, ROS enhance the secretion of proinflammatory
molecules [65]. The release of proinflammatory cytokines in the CNS activate the resident cells
(microglia, astrocytes, and Müller cells) which secrete other proinflammatory cytokines (e.g., TNFs
and INFγ) and interleukins that exacerbate the situation [66]. NAD+ can be directly or indirectly
implicated in all of these mechanisms.
With age, a loss of genome integrity alters both mtDNA and nDNA. DNA damage is common and,
if left unrepaired, can adversely impact cellular homeostasis. The ability to counteract this relies on
SIRTs and in particular SIRT7, which plays a key role in the DNA damage response. This mechanism is
strictly dependent on NAD+ availability and when NAD+ bioavailability is limited these enzymes
cannot exert their function [67]. Mitochondria integrity is strictly dependent on this mechanism,
and mtDNA mutations alter the efficiency of the electron transport chain, generating excess ROS and
limiting mitochondrial biogenesis [68]. Experiments on Deletor mice, a mouse model of mitochondrial
myopathy that carries a mtDNA replicative helicase mutation, have demonstrated that increasing NAD+
by daily administration of nicotinamide riboside (NR) was sufficient to restore mitochondrial function
and to increase mitochondrial turnover [69,70]. Mitochondrial integrity is further protected by UPRmt,
which either through an accurate mitochondrial biogenesis program or metabolic adaptation promotes
cellular viability and mitochondrial recovery [71]. In an oxidative state, this system damages to the
UPRmt which increases with excessive ROS production due to Complex I and III impairment, mtDNA
mutation [71], and excess levels of unfolded or damaged proteins that overcome the mitochondrial
chaperone protein-folding capacity [72]. NAD+ regulation of SIRT3 is implicated in UPRmt proper
function via three diverse mechanisms that either promote mitophagy or activate antioxidant responses,
and alternatively directly reduce protein misfolding and the accumulation of aggregates in the
mitochondria [73,74]. Finally, NAD+ can act as a very powerful anti-inflammatory molecule. Evidence
suggests that this effect is achieved through PARP1 activation and the inhibition of SIRT1. When the
activity of PARP1 is inhibited due to reduced NAD+ availability, this event triggers a detrimental
cellular cascade modulated by multiple pro-inflammatory responses. When NAD+ is replenished by
NAM administration, PARP1 responds to the stimulus and can antagonize SIRT1 activity. This concert
of mutual conditioning due to NAD+ results in the suppression of inflammatory mediators [75].
It is not surprising that interventions to boost NAD+ bioavailability are of great interest, especially
considering the impact that this may have on neurodegenerative disease. Compelling evidence indicates
that deficits in NAD+ production or processing may be drivers of ocular degenerations.
2.3. NAD+ and Eye Disease
The retina is one of the most energy demanding tissues requiring a constant energy supply and
bioenergetic homeostasis to preserve function. In the last decade, the role of NAD+-related impairment
has been highlighted in almost all retinal neurodegenerative disorders [76]. Direct acknowledgement
of NAD+ retina related pathology comes from studies on Leber congenital amaurosis 9 (LCA9), a very
severe retinal dystrophy that lead to complete vision loss caused by mutations in NMNAT1 [77]. Around
ten mutations in the NMNAT1 gene have been identified in genome sequencing of LCA9 carriers [78,79]
and extensive studies on LCA9 retinas have elucidated that NMNAT1 is not only responsible for NAD+
biosynthesis but is required for retinal structure, development, and function [80,81]. Photoreceptors
damage due to NMNAT1 dysfunction is one possible deleterious mechanism demonstrated in AMD.
In mice, a specific deletion of Nampt in rod and cones demonstrated the direct influence of NAD+
metabolism on photoreceptor survival and visual function, highlighting the strong connection with
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mitochondrial deficits in these cells [80]. However, photoreceptors are not the only cellular phenotype
affected by NAD+ decline. In AMD, RPE cells relay on NAD+ energy supply to sustain their metabolic
requirements. Rodent experiments with light-induced retinal damage and ex vivo retinas explant
cultures of AMD mouse models have demonstrated that restoring normal NAD+ either prevents
RPE-induced light insult or reduces the propagation of retinal damage [82–84]. Moreover, restoring
NAD+ levels in AMD retinas decreased ROS RPE damage and significantly reduced the expression
of proinflammatory molecules that are responsible for drusen formation [85,86]. Supporting this,
experiments blocking NMNAT enzymatic activity promoted RPE detriment and induced a pathologic
state that affected photoreceptors, outer and inner nuclear layer, and the plexiform layer [87,88].
In addition to AMD, glaucoma is profoundly connected to NAD+ functions. RGCs, the affected
neuron in glaucoma, are energetically demanding and depend on NAD+. The view of glaucoma as
a NAD+-related pathology has been derived from several scientific studies in which both NMNATs
over-expression and NAD+-related dietary intervention have been involved. NMNAT1 is pivotal
for axonal protection [89,90] and overexpression of NMNAT1 is a component of the Wallerian
degeneration slow allele (WldS) which delays Wallerian degeneration after axonal injury [91,92].
Furthermore, the NAD+ producing enzyme has been shown not only to protect RGCs axons but also
somas in animal models of chronic and acute glaucomatous damage. In experiments using a mouse
model with cytoplasmically located NMNAT1, cytNMNAT1-tg mice, NMNAT1 rescued RGCs from
glaucomatous injury as well as from ischemic damage [93]. However, these neuroprotective effects are
not only limited to NMNAT1. Overexpression of NMNAT3 rescued RGCs from ocular hypertension
induced damage and prevented mitochondrial related insults [28,94]. Williams et al. in an study
using DBA/2J mice, an extensively used mouse model for glaucoma, demonstrated that exogenous
NAD+ in the form of nicotinamide dietary supplementation was capable to restore RGCs function
in both aged and glaucoma-prone mice [95]. This work also demonstrated that viral gene therapy
overexpressing Nmnat1 in RGCs provided a significant neuroprotection, and when used in combination
with nicotinamide administration rescued 94% of eyes from glaucomatous neurodegeneration [96].
This specific intervention protected RGCs soma, synapses, and axons, and prevented the loss of
axoplasmic transport, demonstrating that many glaucoma deficits may be due to mitochondrial
impairments derived by NAD+ disrupted metabolism [97]. RGCs axons are not the only neuronal
compartment affected by the glaucomatous insults with RGC dendrites abruptly affected as well.
Experiments conducted on Drosophila mutants overexpressing Nmnat have demonstrated that NMNAT
is required to preserve dendritic structures, confirming the broad spectrum of NAD+ in the CNS [98].
3. Glaucoma
Glaucoma is characterized by the progressive degeneration of RGCs and their axons which make
up the optic nerve resulting in visual field loss and irreversible blindness [99]. It is the major cause
of irreversible blindness worldwide and its burden has been estimated to affect ~2% of the global
population by 2040 [1]. To date, the only treatable and modifiable risk factor is IOP, however ~40% of
treated glaucoma patients will still continue to be blind in at least one eye [4].
Clinically, glaucoma is divided into primary (open angle and angle closure glaucoma) and secondary
(originating from trauma, medication, inflammation, cancer, or other primary conditions) glaucomas.
Regardless of the initiating events, irreversible RGC neurodegeneration is the neuropathological
hallmark of the disease. This specific class of neurons is located in the inner retina, with their axons
making up the RNFL and the optic nerve. At the optic disc RGCs axons bundle together to exit the eye
becoming the optic nerve, and at the level of the optic chiasm the optic nerve partially decussates to
project to terminal visual thalami in the brain [100,101]. Changes in the RNFL and disc/cup ratio can be
easily identified during an ophthalmoscopic examination [102]. However, it has been documented that
RGCs death is preceded by several structural and functional changes in the dendrites, soma, and axons
that hide from gross clinically detection [103]. This progressive and compartmentalized degeneration
may offer a window for therapeutic interventions that can be useful to halt the underlying mechanisms
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of RGC neurodegeneration [104]. Structural changes of the dendrites, predominantly manifested with
the pruning of the exterior branches, with a consequent impact on the neurotransmission due to
synapses loss, can be detected early upon insult [105–107]. Dendritic architectural remodeling after IOP
increase seems to be correlated not only with altered neuronal trafficking [108,109] but especially with
complement activation [110] and mitochondrial impairments [111,112]. The spread of the axon damage
is not linear and appears to initiate distally from the main site of injury [113], which has been proposed
to be the optic nerve head (ONH) [114,115]. The mechanism by which the damage propagates along
the axon is compartment-related [116] with several lines of evidence reported by Libby et al. in their
studies of axonal degeneration [117,118]. These dramatic architectural changes that affect glaucomatous
RGCs already illustrate the multiple components that are in charge of RGCs degenerative processes.
As such, oxidative stress, inflammation, glial activation, neurotrophin deprivation, and excitotoxicity
(among others) work in concert to drive RGC degeneration [119–123], with mitochondrial dysfunction
being a potential driving force behind these multifactorial processes [124].
Efficient mitochondria are essential for RGCs survival, as evidenced in Leber’s hereditary optic
neuropathy and autosomal dominant optic atrophy (which results in RGC degeneration and irreversible
blindness) [61]. Mitochondria distribution along RGCs is asymmetric due to the different energetic
demand among the RGC compartments, with a higher density in the dendrites and in the unmyelinated
ONH [125,126], which are initial sites of neurodegeneration.
One of the first insults promoted by the mitochondria is the generation of a wide oxidative state
in the cell and when ROS production overcomes the cellular tolerance or in response to other lethal
stimuli, cytochrome c is released in the cytosol where in concert with other cytosolic factors forms the
apoptosome and further promotes other caspase activation [127]. This process, the intrinsic apoptotic
pathway, also activates astrocytes and microglia. In a normal state microglia and astrocytes secrete
factors which are fundamental for RGCs health [128]. One of their roles as CNS resident cells is to sense
metabolic alterations and to act in order to re-establish metabolic homeostasis, but in the presence of
caspase 8 and 3 they become hyperactivated and start to release TNFα and several pro-inflammatory
cytokines [4]. TNFα is the promoter of the extrinsic apoptotic pathway and is one of the main promoters
of RGCs death. RGCs express TNF-R1, which is TNFα receptor, thus the bindings of the cytokine
consequently induces RGCs apoptosis [129]. In addition, when Müller glia, microglia, and astrocytes
are hyperactivated, their harm to RGCs is not limited to the apoptotic cascade but is also due to the
cessation of their neuroprotection and neurotrophic support to the cells [130–133]. RGC deprivation of
nerve growth factor (NGF) [134], brain derived neurotrophic factor (BDNF) [135], ciliary neurotrophic
factor (CNTF) [136], and glial-cell line derived neurotrophic factor (GDNF) [137] have been well
established as a connection with the glaucomatous damage. Cessation of the release of neurotrophic
factors increases the intrinsic apoptotic cascade through the activation of mitogen-activated protein
kinase (MAPK) pathway [138] inducing further mitochondrial dysfunction via BAX [139].
All these catastrophic events are likely to be linked to a decrease in NAD+ [140], and the lack
of effective therapeutic strategies and the remarkable evidence of NAD+ involvement suggest a
therapeutic role for NAD+ in glaucoma.
Available Therapies
All the current available therapies are centered on IOP lowering. The first medical therapy to
achieve IOP lowering was beta adrenoceptor agonists, which reduce the aqueous humor secretion
blocking ciliary epithelium β-receptor [141]. These medications are normally once or twice daily
but unfortunately are not free from adverse effects (e.g., interact with the heart rhythm or causing
bronchospasm [142]) that sometimes might render the adherence to therapy difficult or even not
recommended. To overcome this obstacle, rho kinases inhibitors therapies have been introduced,
with some side effects reduction and quite few improvements in RGCs survival [143]. Unluckily,
these therapies are not always effective and when they fail the only two alternative approaches are
much more invasive and rely either on laser therapy or surgical interventions [144]. Both argon laser
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trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) or micropulse laser trabeculoplasty
(MLT) aim to open the space at the trabecular meshwork [145]. Although sometimes effective at
an IOP level, they may provoke an inflammatory state that, as discussed in the previous section,
only aggravates the general pathological state. However, even this strategy can fail, resulting in surgery
as a final option for many patients (e.g., trabeculectomy) [146].
4. Age-Related Macular Degeneration
Age-related macular degeneration is one of the leading causes of visual function impairments.
One of the main risk factors, as implicated by the disease name, is aging, yet it is a multifactorial disease
in which inflammation, metabolic dysfunctions, environmental factors, and genetic predisposition
play a fundamental role. Clinically, AMD is classified as dry and wet, with the dry form accounting
for 90% of cases and has a slower progression. The late and severe form of dry AMD is referred to as
geographic atrophy (GA) and is characterized by a marked degeneration of RPE cells, photoreceptor
loss, and degraded choriocapillaris [147]. Wet AMD accounts for the other 10% of cases and has
a much faster progression and severe prognosis. At the latest stage, wet AMD shows abnormal
vessels growth below the retina and that is why it is referred to as the choroidal neovascularization
(CNV) form, with the CNV that breaks through the neural retina with an exudate of lipids, fluid,
and blood [148]. One of the first signs that may suggest the progression to AMD is the development
of drusen, yellow extracellular deposits that accumulated between the basal lamina of the RPE and
the inner collagenous layer of the Bruch’s membrane. Their size and “softness” is one of the used
parameters for identify the risk for developing AMD [149]; generally, small and hard drusen below
63 µm are considered as low risk, while drusen up to 125 µm are considered already an early sign of
AMD. Hard drusen can become soft and more extended (above 125 µm), causing RPE abnormalities
and spreading to the macula [150]. Until the 1970s, drusen were thought to be local deposits of lipids
and carbohydrates but more recent knowledge has demonstrated the inclusion of elements of intra-
and extraocular sources such as complement components and protein waste material, aligning with
the involvement of several active processes participating in AMD development [151]. However, if we
approach AMD with a molecular perspective, the pathological steps that drive photoreceptor apoptosis
become clearer and provide a better understanding of this complex disease.
Oxidative stress is one of the leading pathological causes. For its structure and function, the retina
is one of the highest oxygen-consuming organs, with the highest concentration of oxygen in the
choroid that progressively decrease at the lower concentration in the outer segment of the retina [152].
This anatomical distribution generates an oxygen gradient along the retinal tissue that predispose
to the photoreceptor oxidative damage [153]. Mitochondria are the first contributing factor to AMD
oxidative stress, as elucidated from AMD animal models, some of which involve the knockdown
of SOD2 (an isoform of the superoxide dismutase expressed in the mitochondria). Analysis of
histological sections from these models showed a marked degeneration of the RPE with a conspicuous
photoreceptor atrophy [154]. Other evidence of mitochondrial involvement came from Jones et al.,
who found specific mtDNA mutations in tissue samples of AMD patients [155,156]. Another study
supporting a primary mitochondrial involvement in AMD comes from a study on primary culture
of RPE cells from donors with AMD, wherein Ebeling et al. could demonstrate an improvement in
mitochondrial function with a decrease in RPE cells loss upon Rapamycin and NAM treatment [157].
Mitochondrial dysfunctions significantly contribute to AMD related inflammation activating the
nucleotide-binding oligomerization domain (NOD)-like receptor family or inducing the inflammasome
activation, for example [158]. In response to the oxidative damage, macrophage infiltrates have been
found in the subretinal space, in the choroid, and close to the drusen [159,160]. There are two subclasses
of macrophages, M1 and M2; M2 are the anti-inflammatory macrophages that have been found to
be predominant in the first pathological stage, performing a house-keeping role to minimize the
damage, while M1, the pro-inflammatory macrophages, are the most conspicuous in the advanced
stage and their role is to sustain and aggravate the inflammatory reaction, stimulating TNFα release,
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disrupting the balance among IL-1β and IL-18 that promote inflammasome related tissue-injury [161],
and impairing autophagy and mitophagy [162]. Besides macrophages, complement activation also
plays a substantial part in the AMD chronic inflammatory state. RPE cells constitutively express many
complement pathway components that can be upregulated by both macrophages and microglia secreted
molecules [163,164]. There are three main pathways that are involved in complement activation; all lead
to C3 activation and the subsequent complement cascade. Complement factor H (CFH), which is an
important regulatory protein that controls the activation of C3, has been found mutated in genetic
screening of familial AMD, confirming the role of complement involvement in the pathogenesis of
AMD [165].
Considering that AMD is a multifactorial disease and exists in two forms, the reduced oxygen
supply from the choroid to the outer retina, namely retinal hypoxia, participates in the development
of wet AMD [166]. Anatomical changes in the retina caused by accumulated drusen, increased
Bruch’s membrane thickness or even the changing in the RPE layer, create a space between the
choriocapillaris and the retina, thus forming a physical barrier which prevents an adequate oxygen
supply. This mechanism stimulates VEGF to promote angiogenesis, but instead of restoring balanced
oxygen levels it promotes edema with further retinal detachment that worsen the situation increasing
hypoxia and VEGF production [167,168]. One of the factors responsible for VEGF production is the
hypoxia-inducible factor-1α (HIF-1α). HIF-1α activity in normoxic conditions is inhibited but when
the retina either detects an oxygen reduction or is stimulated by inflammatory mediators, such as
TNFα, promotes VEGF expression [169,170]. The first study that was able to demonstrate the link
between HIF-1α and VEGF expression in an animal model of ocular neovascularization was conducted
by Lin et al. in 2012 [171]. In 2015, a pivotal study conducted by André et al. confirmed the same
altered mechanisms in wet AMD. André et al.’s experiment demonstrated that following the induction
of lesions mimicking CNV, an hypoxic state was detectable a few days after the insult, with the
concurrent accumulation of HIF-1α in the tissue and subsequent upregulation of VEGF in the model’s
neoangiogenic phase [172]. Furthermore, their experiment confirmed the hypothesis that HIF-1α
expression was not correlated with the choroidal tissues but with the RPE cells [173,174].
The mechanisms that lead to vision loss in AMD act in concert and initiate a complex cycle that
still needs to be completely clarified. Hanus et al. commented that it is still debatable if RPE cells loss
is due to apoptosis or necrosis, which has broad implications on how we view and design treatments
for AMD [175]. However, it was suggested by Rozing et al. that a two-level AMD pathological
mechanism may offer a hypothetic therapeutic window prior to the development of the advanced
disease stage. To simplify, they proposed that AMD might be firstly promoted by inflammatory
and external modifiable factors (e.g., smoking, unhealthy lifestyle, and nutritional imbalance) that
render the body susceptible to damage. Once weakened by these factors, the body cannot cope
with the accumulated damage, and therefore reacts initiating the myriad of inflammatory responses
aforementioned, firstly with the aim to repair the damage but then precariously progressing into a
sustained chronic inflammation [176]. To that extent, although this extensive metabolic imbalance
appears to be primarily focus on RPE cell loss, the cause of irreversible blindness is the secondary
profound loss of photoreceptors, rod and cones, that cannot sustain this pronounced energy shortfall
due to mitochondrial dysfunction and macrophage infiltration [177,178] (for an exhaustive review on
these mechanisms, refer to [178]). In the absence of effective therapy, we hypothesize that we should
develop preventive treatment for the first phase and curative treatment for the second phase.
4.1. Available Therapies
4.1.1. Wet AMD
The treatment and management of AMD is as complex as the pathology, and thus far no effective
disease modifying therapies for dry AMD have been validated. The first line approach for wet AMD
targets the final common pathway in the development of CNV, namely VEGF. Anti-VEGF treatment
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seems to be effective in the majority of cases. The first treatment approved in 2004 by the FDA was
pegaptanib, an RNA aptamer that binds the VEGF-165 isoform; ranibizumab, a newer Fab monoclonal
antibody that inhibits the biologically active VEGF-A isoform has given better results on advanced
CNV patients as assessed by the ANCHOR and MARINA trials [179,180]. Such antibodies were
borrowed from the field of cancer treatment, as it was found effective in reducing angiogenesis in
several carcinomas. Although effective the adverse side effects have led to the introduction of a new
anti-VEGF treatment is 2011, aflibercept, that showed affinity to all forms of VEGF [7]. There are
generally four therapeutic regimes adopted in clinical practice: fixed monthly or bimonthly regime of
anti-VEGF intravitreal injections; a rata strategy; a treat-and-extend regimen; and an observe-and-plan
regimen [181]. When these approaches fail, anti-VEGF treatments are used in combination with
transpupillary thermotherapy, which delivers infrared spectrum wave lengths to target the tissue.
In some cases, treatment with anti-VEGF is used in combination with steroids and photodynamic
therapy [182,183]. Lastly, one of the newest approach for CNV AMD is pegpleranib, an inhibitor of
platelet-derived growth factor (anti-PDGF), which promotes pericyte density decrease in the neovascular
membrane to promote a beneficial environment for anti-VEGF agents [184]. Surgical procedures have
been attempted with limited success, causing more harm than benefit. Both submacular surgery and
macular translocation generally produce extensive hemorrhage and are associated with serious risks
as retinal detachment or proliferative vitreoretinopathy [185,186].
4.1.2. Dry AMD
The treatment available for dry AMD are very few and are mostly based on prevention and
intervention at the earliest detectable pathological signs [148]. Fundamentally, the standard treatments
relay on AREDS and AREDS2 recommendations because oxidative stress and inflammation are the
triggering causes for GA AMD. Indeed, in a not yet approved therapeutic regime, patients with
GA are receiving intravitreal injections of lampalizumab, a monoclonal antibody which selectively
inhibit complement factor D. To date, in this MAHALO study, patients displayed a 20% reduction of
the GA area, and, with continued intravitreal administration of the drug, in the CHROMA and the
SPECTRI studies, the proportion of the area affected was reduced to 44% [187,188]. Since inflammation
is considered the pivotal cause for the detrimental complement cascade, oral administration of
tetracycline has provided some promising results [189,190]. In addition to those, there are ongoing
clinical trials with possible lipid-lowering anti-inflammatory drugs (e.g., statins) and mitochondrial
protective compounds such as MTP-131, commercially named Ocuvia, but unfortunately are still
inconclusive [7]. Transplantation of photoreceptor and RPE cells derived from stem cells seem promising
yet considerably invasive. Few patients have attempted this therapeutic approach, and the positive
outcome suggested that, while less invasive treatments are not discovered, cell-based therapies will
become the first line treatment for advanced dry AMD [191]. Other promising therapeutic concepts
are based on targeting the inflammasome, downregulating cytokines, or finding an effective general
neuroprotector but thus far nothing is available for an effective cure.
5. Supplementing NAD+ as a Therapeutic Approach/Strategy in Glaucoma and AMD
Supporting retinal health is at the core of maintaining retinal function. Despite the diversity of
insults that can affect the retina, there are several common pathogenic mechanisms that may permit a
unified therapy: mitochondrial dysfunction, oxidative stress, inflammation, and the inability to clear
waste material from metabolic reactions. These are all mechanistically linked by the bioavailability of
NAD+, either to insufficient production or over-consumption by NAD-consuming enzymes (e.g., SIRTs
and PARPs) [192]. Given this, we propose increasing NAD+ as a putative effective therapeutic strategy
for both glaucoma and AMD.
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5.1. Potentials of NAD+ Intervention in Glaucoma
NAD+ increase, either by NAD+ precursor administration or gene therapy, is able to restore a
normal phenotype and prevent age and disease related changes in the glaucoma mouse model [95–97].
The fact that NAD+ intervention does not target IOP but acts at the triggering pathological events
allows nicotinamide (or other strategies to increase NAD+ pools) to be powerful tools in glaucoma
treatment [193].
The decrease of NAD+ with age is physiological and may not always be related to disease
processes directly. However, this appears not to be in the case in glaucoma. Supporting a hypothesis
in which decreased levels of NAD+ render RGCs susceptible to glaucomatous neurodegeneration,
Kouassi Nzoughet et al. demonstrated decreased sera NAD+ in a cohort of 34 POAG individuals [194].
A paper from Hui et al. [195] specifically highlights this point, translating animal and pre-clinical
findings into clinical practice. In a clinical study of 57 glaucoma participants using inner retina visual
function as the primary outcome measure, Hui and colleagues demonstrated a significant improvement
in the visual function of existing glaucoma patients receiving 3 g/day nicotinamide for 12 weeks in
addition to IOP lowering medication. Although the focus of glaucoma is mainly oxidative stress and
inflammation, autophagic dysfunction, even if minor, plays a role in the pathology [124]. Accumulation
of waste material in the lamina cribrosa (LC) and accumulation of lipofuscin have been found in LC
donors cells with a consequence on dysregulated autophagic clearance at the level of LC with a clear
impact on the ONH [196]. Targeting this other mechanism might be a problem considering the multitude
of glaucoma correlated events if would not be treatable in the same way as the others, however NAD+ is
strongly linked to autophagy suggests its utility here as well [197,198]. The neuroprotection afforded by
nicotinamide may not only be due to improved mitochondrial function but also due to the NAD+/SIRT1
axis [199,200] or to protection from various other insults that affect RGCs, such as ischemia/reperfusion
or light [201]. As such, further studies are needed to fully elucidate the role of nicotinamide and
elevated NAD+ in healthy, diseased, and treated states.
5.2. Potentials of NAD+ Intervention in Age-Related Macular Degeneration
Restoring NAD+ might counteract some of the putative deficits that are most significant in the
mechanisms for AMD development. Mitochondrial dysfunction appears to be the at bottom of the
pyramid of AMD degenerative processes, not only due to mitochondrial involvement in oxidative stress
but also as a dysfunctional organelle that has lost the capability to be replaced [158]. Mitochondrial
homeostasis is regulated by mitochondrial biogenesis, fusion and fission, mitochondrial quality control,
and mitochondrial autophagy (mitophagy). The process of mitophagy, in which damaged mitochondria
are degraded and recycled, is pivotal for neuronal functions and the prevention of pathological neuronal
dysfunction [202]. Impairments in this process have been associated with AMD and NAD+ may be a
potential solution for the impaired mitophagy [203,204]. PINK1 and PARKIN, which are responsible
of the proper degradation of damaged mitochondria via mitophagy, appear to be upregulated
in a mouse model of dry AMD, the erythroid 2-related factor 2/peroxisome proliferator-activated
receptor gamma coactivator 1-alpha double knockdown, NFE2L2/PGC-1α−/− mouse model [205].
The analysis of NFE2L2/PGC-1α−/− RPE cells displayed an extensive upregulation of PINK and
PARKIN levels along with an impaired mitochondrial clearance system, showing all the phenotypical
change related to AMD [206]. PGC-1α governs the mitochondrial quality control system, and this
function is enabled by the NAD+/SIRT1 axis. Restoring NAD+ levels compensate for the unbalanced
SIRT1 activity re-establishing mitochondrial biogenesis, mitophagy, and UPRmt [207]. Activating SIRT1
activity through NAD+ allows the deacetylation of several mitophagy-involved proteins such as
Atg5, Atg7, and Atg8, bringing back or restoring to a normal level the mitochondrial quality control
system [207,208]. Other lines of inquiry have reported that, instead of the NAD+/SIRT1/Atg5-7-8 axis,
mitophagy is restored through the effect of NAD+/SIRT1/ULK1, confirming a profound involvement
of this molecule in mitochondrial function [209]. Furthermore, the demonstration of the ability of
NAD+ to halt the detrimental process in AMD comes from Saini et al. [210]. In this study, using human
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induced-pluripotent stem cells (hiPSC)-derived RPE cell line from AMD donors, NAD+ was capable
of improving all the disease related features of AMD, such as drusen formation, complement-driven
inflammation, mitochondrial dysfunction, and VEGF expression [210], supporting a hypothesis for
NAD+ as a valuable treatment for both dry and wet AMD. Lastly, NAD+ has been shown to ameliorate
another altered mechanism that affects RPE cells during AMD, a process called epithelial–mesenchymal
transition (EMT). ETM consists in the loss of epithelial cell polarity and cell-cell adhesion and the
acquisition of migratory and invasive properties as mesenchymal stem cells. This process RPE-ETM
has been found to be linked to TGF-β upregulation, UPRmt dysfunctions, yet, as reported by Zhou et al.
and Hyttinen et al., NAM treatment prevented ETM in numerous RPE cell models, orchestrating the
mechanism responsible for that shift [211,212].
5.3. Safety of NAD+ Supplementation
An increase in cellular NAD+ pools can be obtained from several exogenous sources including NR,
NA, NMN, and NAM. Increasing evidence of the neuroprotective and positive aging effects of NAD+
precursors has intensified research concerning their safety level and side effects. All these precursors
collectively fall under the umbrella of vitamin B3 replacement, even though their recommended intake
is widely different. Although within therapeutic range, doses above 50 mg/day of NA are not advised
due to flushing. Chronic intake of 3 g/day of NAM is well tolerated with side effects (mostly gastric
minor disturbance) only in a small percentage of patients [213]. In classic studies from the 1950s
and onwards, long-term higher doses of NAM at >9 g/day have been reported with minimal side
effects, and some of the flushing side effects noted in these studies are likely from impure preparation,
which include an admixture of NAM and NA [214]. NMN and NR are well tolerated as well, but the
effects of long-term chronic administration are yet to be assessed fully in humans. One gram per day
of NR was enough to improve both cardiovascular functions and lipid metabolism associated with
increased NAD+ pool, which suggests tolerance, and possibly safety, at least at this dose level [215,216].
6. Conclusions
Glaucoma and AMD are common, irreversible, degenerative diseases with an urgent therapeutic
need. The core of the deficits in these diseases may be reduced directly or indirectly to two
main sources: physiological age-related NAD pool depletion and mitochondrial dysfunction.
Supporting mitochondrial function is likely to be a promising strategy to inhibit neurodegenerative
disease progression along with NAD+ repletion as an effective approach to restore normal function
and cellular homeostasis. Recent evidence in human and animal models, as well as recent clinical trial
evidence for nicotinamide treatment in glaucoma, highlights the potential for NAD+-related therapies
for glaucoma and AMD, and potentially other age- and metabolism-related neurodegenerative diseases.
The wide availability, affordability, safety, and tolerability of nicotinamide and other NAD+ precursors
support further long-term clinical testing as well as potentially immediate clinical use.
Author Contributions: G.C. planned and wrote the manuscript and performed the literature review; J.E.M. edited
the manuscript and provided literature and expertise; M.V. edited the manuscript and provided literature and
expertise; H.A. conceptualized the review, planned and edited the manuscript, and provided literature and
expertise; and P.A.W. conceptualized the review, planned and edited the manuscript, and provided literature and
expertise. All authors have read and agreed to the published version of the manuscript.
Funding: Fight for Sight Studentship (515905; James Morgan) and Vetenskapsrådet (the Swedish Research Council;
2018-02124; Pete Williams) provided funding. Pete Williams is supported by the Karolinska Institutet in the form
of a Board of Research Faculty Funded Career Position. Pete Williams and Helder André are supported by St. Erik
Eye Hospital philanthropic donations.
Acknowledgments: The authors would like to thank Anders Kvanta for insightful scientific discussion and
James Tribble for help with the graphical abstract.
Conflicts of Interest: The authors declare no conflict of interest.
Nutrients 2020, 12, 2871 12 of 21
References
1. Tham, Y.C.; Li, X.; Wong, T.Y.; Quigley, H.A.; Aung, T.; Cheng, C.Y. Global prevalence of glaucoma and
projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 2014,
121, 2081–2090. [CrossRef] [PubMed]
2. Wong, W.L.; Su, X.; Li, X.; Cheung, C.M.G.; Klein, R.; Cheng, C.Y.; Wong, T.Y. Global prevalence of
age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and
meta-analysis. Lancet Glob. Health 2014, 2, e106–e116. [CrossRef]
3. Jonas, J.B.; Aung, T.; Bourne, R.R.; Bron, A.M.; Ritch, R.; Panda-Jonas, S. Glaucoma. Lancet 2017, 390, 2183–2193.
[CrossRef]
4. Almasieh, M.; Wilson, A.M.; Morquette, B.; Cueva Vargas, J.L.; Di Polo, A. The molecular basis of retinal
ganglion cell death in glaucoma. Prog. Retin. Eye Res. 2012, 31, 152–181. [CrossRef] [PubMed]
5. Lee, D.A.; Higginbotham, E.J. Glaucoma and its treatment: A review. Am. J. Health Syst. Pharm. 2005, 62,
691–699. [CrossRef]
6. Hoyng, P.F.J.; Kitazawa, Y. Medical treatment of normal tension glaucoma. Surv. Ophthalmol. 2002, 47,
S116–S124. [CrossRef]
7. Al-Zamil, W.M.; Yassin, S.A. Recent developments in age-related macular degeneration: A review. Clin. Interv.
Aging 2017, 12, 1313–1330. [CrossRef]
8. Algvere, P.V.; Kvanta, A.; Seregard, S. Drusen maculopathy: A risk factor for visual deterioration.
Acta Ophthalmol. 2016, 94, 427–433. [CrossRef]
9. Hernandez-Zimbron, L.F.; Zamora-Alvarado, R.; Ochoa-De la Paz, L.; Velez-Montoya, R.; Zenteno, E.;
Gulias-Canizo, R.; Quiroz-Mercado, H.; Gonzalez-Salinas, R. Age-related macular degeneration: New
paradigms for treatment and management of AMD. Oxid. Med. Cell Longev. 2018, 2018, 8374647. [CrossRef]
10. Velez-Montoya, R.; Oliver, S.C.N.; Olson, J.L.; Fine, S.L.; Mandava, N.; Quiroz-Mercado, H. Current
knowledge and trends in age-related macular degeneration: Today’s and future treatments. Retina 2013, 33,
1487–1502. [CrossRef]
11. Velez-Montoya, R.; Oliver, S.C.N.; Olson, J.L.; Fine, S.L.; Quiroz-Mercado, H.; Naresh, M. Current knowledge
and trends in age-related macular degeneration: Genetics, epidemiology, and prevention. Retina 2014, 34,
423–441. [CrossRef] [PubMed]
12. ClinicalTrials.gov. Available online: https://clinicaltrials.gov (accessed on 18 September 2020).
13. Chew, E.Y. The age-related eye disease study (AREDS) and AREDS 2 supplements in 2018. Retin. Physician
2018, 15, 31–34.
14. Grunwald, J.E.; Pistilli, M.; Daniel, E.; Ying, G.S.; Pan, W.; Jaffe, G.J.; Toth, C.A.; Hagstrom, S.A.; Maguire, M.G.;
Martin, D.F. Incidence and growth of geographic atrophy during 5 years of comparison of age-related
macular degeneration treatments trials. Ophthalmology 2017, 124, 97–104. [CrossRef]
15. Verdin, E. NAD+ in aging, metabolism, and neurodegeneration. Science 2015, 350, 1208–1213. [CrossRef]
16. Mattson, M.P.; Arumugam, T.V. Hallmarks of brain aging: Adaptive and pathological modification by
metabolic states. Cell Metab. 2018, 27, 1176–1199. [CrossRef] [PubMed]
17. Boatright, J. NAD+/NADH precursor treatment protects against retinal degeneration. Acta Ophthalmol.
2019, 97. [CrossRef]
18. Di Marco, S.; Carnicelli, V.; Franceschini, N.; Di Paolo, M.; Piccardi, M.; Bisti, S.; Falsini, B. Saffron: A multitask
neuroprotective agent for retinal degenerative diseases. Antioxidants 2019, 8, 224. [CrossRef]
19. Heitmar, R.; Brown, J.; Kyrou, I. Saffron (Crocus sativus L.) in ocular diseases: A narrative review of the
existing evidence from clinical studies. Nutrients 2019, 11, 649. [CrossRef]
20. Demmig-Adams, B.; Lopez-Pozo, M.; Stewart, J.J.; Adams, W.W., III. Zeaxanthin and lutein: Photoprotectors,
anti-inflammatories, and brain food. Molecules 2020, 25, 3607. [CrossRef]
21. Murillo, A.G.; Hu, S.; Fernandez, M.L. Zeaxanthin: Metabolism, properties, and antioxidant protection of
eyes, heart, liver, and skin. Antioxidants 2019, 8, 390. [CrossRef]
22. Williams, P.A.; Harder, J.M.; Guymer, C.; Wood, J.P.M.; Daskalaki, E.; Chidlow, G.; Cardozo, B.H.;
Foxworth, N.E.; Cochran, K.E.; Ouellette, T.B.; et al. Oral pyruvate prevents glaucomatous neurodegeneration.
bioRxiv 2020. [CrossRef]
23. Harden, A.; Young, W.J.; Martin, C.J. The alcoholic ferment of yeast-juice. Proc. R. Soc. Lond. Ser. B Contain.
Pap. Biol. Character 1906, 77, 405–420. [CrossRef]
Nutrients 2020, 12, 2871 13 of 21
24. Harden, A.; Young, W.J.; Martin, C.J. The alcoholic ferment of yeast-juice. Part II.—The coferment of
yeast-juice. Proc. R. Soc. Lond. Ser. B Contain. Pap. Biol. Character 1906, 78, 369–375. [CrossRef]
25. Morabia, A. Joseph Goldberger’s research on the prevention of pellagra. J. R. Soc. Med. 2008, 101, 566–568.
[CrossRef]
26. Lautrup, S.; Sinclair, D.A.; Mattson, M.P.; Fang, E.F. NAD(+) in Brain Aging and Neurodegenerative Disorders.
Cell Metab. 2019, 30, 630–655. [CrossRef] [PubMed]
27. Felicitas Berger, C.L.; Dahlmann, M.; Ziegler, M. Subcellular Compartmentation and Differential Catalytic
Properties of the Three Human Nicotinamide Mononucleotide Adenylyltransferase Isoforms. J. Biol. Chem.
2005, 280, 36334–36341. [CrossRef] [PubMed]
28. Tang, B.L. Why is NMNAT protective against neuronal cell death and axon degeneration, but inhibitory of
axon regeneration? Cells 2019, 8, 267. [CrossRef]
29. Gilley, J.; Mayer, P.R.; Yu, G.; Coleman, M.P. Low levels of NMNAT2 compromise axon development and
survival. Hum. Mol. Genet. 2018, 28, 448–458. [CrossRef]
30. Gilley, J.; Coleman, M.P. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy
axons. PLoS Biol. 2010, 8, e1000300. [CrossRef]
31. Hicks, A.N.; Lorenzetti, D.; Gilley, J.; Lu, B.; Andersson, K.E.; Miligan, C.; Overbeek, P.A.; Oppenheim, R.;
Bishop, C.E. Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) regulates axon integrity in the
mouse embryo. PLoS ONE 2012, 7, e47869. [CrossRef]
32. Di Stefano, M.; Loreto, A.; Orsomando, G.; Mori, V.; Zamporlini, F.; Hulse, R.P.; Webster, J.; Donaldson, L.F.;
Gering, M.; Raffaelli, N.; et al. NMN deamidase delays wallerian degeneration and rescues axonal defects
caused by NMNAT2 deficiency in vivo. Curr. Biol. 2017, 27, 784–794. [CrossRef] [PubMed]
33. Loreto, A.; Hill, C.S.; Hewitt, V.L.; Orsomando, G.; Angeletti, C.; Gilley, J.; Lucci, C.; Sanchez-Martinez, A.;
Whitworth, A.J.; Conforti, L.; et al. Mitochondrial impairment activates the Wallerian pathway through
depletion of NMNAT2 leading to SARM1-dependent axon degeneration. Neurobiol. Dis. 2019, 134, 104678.
[CrossRef] [PubMed]
34. Sauve, A.A. NAD+ and Vitamin B3: From metabolism to therapies. J. Pharmacol. Exp. Ther. 2008, 324,
883–893. [CrossRef] [PubMed]
35. Opitz, C.A.; Heiland, I. Dynamics of NAD-metabolism: Everything but constant. Biochem. Soc. Trans. 2015,
43, 1127–1132. [CrossRef] [PubMed]
36. Castro-Portuguez, R.; Sutphin, G.L. Kynurenine pathway, NAD+ synthesis, and mitochondrial function:
Targeting tryptophan metabolism to promote longevity and healthspan. Exp. Gerontol. 2020, 132, 110841.
[CrossRef]
37. Preiss, J.; Handler, P. Biosynthesis of diphosphopyridine nucleotide I. Identification of intermediates. J. Biol.
Chem. 1958, 233, 488–492.
38. Preiss, J.; Handler, P. Biosynthesis of diphosphopyridine nucleotide II. Enzymatic aspects. J. Biol. Chem. 1958,
233, 493–500.
39. Song, S.B.; Park, J.S.; Chung, G.J.; Lee, I.H.; Hwang, E.S. Diverse therapeutic efficacies and more diverse
mechanisms of nicotinamide. Metabolomics 2019, 15, 137. [CrossRef]
40. Brenner, P.B.A.C. Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a
Preiss-Handler Independent Route to NAD+ in Fungi and Humans. Cell 2004, 117, 495–502.
41. Poddar, S.K.; Sifat, A.E.; Haque, S.; Nahid, N.A.; Chowdhury, S.; Mehedi, I. Nicotinamide Mononucleotide:
Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules 2019, 9, 34. [CrossRef]
42. Imai, S.-I.; Armstrong, C.M.; Kaeberlein, M.; Guarente, L. Transcriptional silencing and longevity protein
Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403, 795–800. [CrossRef]
43. Quarona, V.; Zaccarello, G.; Chillemi, A.; Brunetti, E.; Singh, V.K.; Ferrero, E.; Funaro, A.; Horenstein, A.L.;
Malavasi, F. CD38 and CD157: A long journey from activation markers to multifunctional molecules.
Cytom. Part B Clin. Cytom. 2013, 84B, 207–217. [CrossRef] [PubMed]
44. Kim, M.Y.; Zhang, T.; Kraus, W.L. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear
signal. Genes Dev. 2005, 19, 1951–1967. [CrossRef] [PubMed]
45. Rasti, G.; Simonet, N.G.; Vaquero, A. Niacin. In Principles of Nutrigenetics and Nutrigenomics; Academic press:
Cambridge, MA, USA, 2020; pp. 287–293.
46. Katsyuba, E.; Romani, M.; Hofer, D.; Auwerx, J. NAD+ homeostasis in health and disease. Nat. Metab. 2020,
2, 9–31. [CrossRef] [PubMed]
Nutrients 2020, 12, 2871 14 of 21
47. Audrito, V.; Manago, A.; Gaudino, F.; Sorci, L.; Messana, V.G.; Raffaelli, N.; Deaglio, S. NAD-Biosynthetic and
Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses
in Cancer. Front. Immunol. 2019, 10, 1720. [CrossRef] [PubMed]
48. Tissenbaum, H.A.; Guarente, L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans.
Nature 2001, 410, 227–230. [CrossRef] [PubMed]
49. Rogina, B.; Helfand, S.L.; Frankel, S. Longevity Regulation by Drosophila Rpd3 Deacetylase and Caloric
Restriction. Science 2002, 298, 1745. [CrossRef]
50. Verdin, E. The Many Faces of Sirtuins: Coupling of NAD metabolism, sirtuins and lifespan. Nat. Med. 2014,
20, 25–27. [CrossRef]
51. Van der Veer, E.; Ho, C.; O’Neil, C.; Barbosa, N.; Scott, R.; Cregan, S.P.; Pickering, J.G. Extension of human
cell lifespan by nicotinamide phosphoribosyltransferase. J. Biol. Chem. 2007, 282, 10841–10845. [CrossRef]
52. Hegyi, J.; Schwartz, R.A.; Hegyi, V. Pellagra: Dermatitis, dementia, and diarrhea. Int. J. Dermatol. 2004, 43,
1–5. [CrossRef]
53. Schultz, M.B.; Sinclair, D.A. Why NAD(+) Declines during Aging: It’s Destroyed. Cell Metab. 2016, 23,
965–966. [CrossRef] [PubMed]
54. Gasperi, V.; Sibilano, M.; Savini, I.; Catani, M.V. Niacin in the Central Nervous System: An Update of
Biological Aspects and Clinical Applications. Int. J. Mol. Sci. 2019, 20, 974. [CrossRef] [PubMed]
55. Fricker, R.A.; Green, E.L.; Jenkins, S.I.; Griffin, S.M. The Influence of Nicotinamide on Health and Disease in
the Central Nervous System. Int. J. Tryptophan. Res. 2018, 11, 1178646918776658. [CrossRef] [PubMed]
56. Canto, C.; Menzies, K.J.; Auwerx, J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing
Act between Mitochondria and the Nucleus. Cell Metab. 2015, 22, 31–53. [CrossRef] [PubMed]
57. Wang, X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001, 15, 2922–2933. [PubMed]
58. Fang, E.F.; Lautrup, S.; Hou, Y.; Demarest, T.G.; Croteau, D.L.; Mattson, M.P.; Bohr, V.A. NAD(+) in Aging:
Molecular Mechanisms and Translational Implications. Trends Mol. Med. 2017, 23, 899–916. [CrossRef]
[PubMed]
59. Chaban, Y.; Boekema, E.J.; Dudkina, N.V. Structures of mitochondrial oxidative phosphorylation
supercomplexes and mechanisms for their stabilisation. Biochim. Biophys. Acta 2014, 1837, 418–426. [CrossRef]
60. Reinecke, F.; Smeitink, J.A.; van der Westhuizen, F.H. Oxphos gene expression and control in mitochondrial
disorders. Biochim. Biophys. Acta 2009, 1792, 1113–1121. [CrossRef]
61. Ito, Y.A.; Di Polo, A. Mitochondrial dynamics, transport, and quality control: A bottleneck for retinal ganglion
cell viability in optic neuropathies. Mitochondrion 2017, 36, 186–192. [CrossRef]
62. Srivastava, S. The Mitochondrial Basis of Aging and Age-Related Disorders. Genes 2017, 8, 398. [CrossRef]
63. Ermak, G.; Davies, K.J.A. Calcium and oxidative stress: From cell signaling to cell death. Mol. Immunol.
2002, 38, 713–721. [CrossRef]
64. Orrenius, S.; Gogvadze, V.; Zhivotovsky, B. Calcium and mitochondria in the regulation of cell death.
Biochem. Biophys. Res. Commun. 2015, 460, 72–81. [CrossRef] [PubMed]
65. Solleiro-Villavicencio, H.; Rivas-Arancibia, S. Effect of Chronic Oxidative Stress on Neuroinflammatory
Response Mediated by CD4(+)T Cells in Neurodegenerative Diseases. Front. Cell Neurosci. 2018, 12, 114.
[CrossRef] [PubMed]
66. Li, L.; Eter, N.; Heiduschka, P. The microglia in healthy and diseased retina. Exp. Eye Res. 2015, 136, 116–130.
[CrossRef] [PubMed]
67. Vazquez, B.N.; Thackray, J.K.; Serrano, L. Sirtuins and DNA damage repair: SIRT7 comes to play. Nucleus
2017, 8, 107–115. [CrossRef]
68. Lee, C.F.; Caudal, A.; Abell, L.; Nagana Gowda, G.A.; Tian, R. Targeting NAD(+) Metabolism as Interventions
for Mitochondrial Disease. Sci. Rep. 2019, 9, 3073. [CrossRef] [PubMed]
69. Lightowlers, R.N.; Chrzanowska-Lightowlers, Z.M. Salvaging hope: Is increasing NAD(+) a key to treating
mitochondrial myopathy? EMBO Mol. Med. 2014, 6, 705–707. [CrossRef]
70. Khan, N.A.; Auranen, M.; Paetau, I.; Pirinen, E.; Euro, L.; Forsström, S.; Pasila, L.; Velagapudi, V.; Carroll, C.J.;
Auwerx, J.; et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.
EMBO Mol. Med. 2014, 6, 721–731. [CrossRef]
71. Shpilka, T.; Haynes, C.M. The mitochondrial UPR: Mechanisms, physiological functions and implications in
ageing. Nat. Rev. Mol. Cell Biol. 2018, 19, 109–120. [CrossRef]
Nutrients 2020, 12, 2871 15 of 21
72. Pellegrino, M.W.; Nargund, A.M.; Haynes, C.M. Signaling the mitochondrial unfolded protein response.
Biochim. Biophys. Acta 2013, 1833, 410–416. [CrossRef]
73. Papa, L.; Germain, D. SirT3 regulates the mitochondrial unfolded protein response. Mol. Cell Biol. 2014, 34,
699–710. [CrossRef] [PubMed]
74. Imai, S.; Guarente, L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014, 24, 464–471. [CrossRef]
[PubMed]
75. Yanez, M.; Jhanji, M.; Murphy, K.; Gower, R.M.; Sajish, M.; Jabbarzadeh, E. Nicotinamide Augments the
Anti-Inflammatory Properties of Resveratrol through PARP1 Activation. Sci. Rep. 2019, 9, 10219. [CrossRef]
[PubMed]
76. Jadeja, R.N.; Thounaojam, M.C.; Bartoli, M.; Martin, P.M. Implications of NAD(+) Metabolism in the Aging
Retina and Retinal Degeneration. Oxid. Med. Cell Longev. 2020, 2020, 2692794. [CrossRef] [PubMed]
77. Sasaki, Y.; Margolin, Z.; Borgo, B.; Havranek, J.J.; Milbrandt, J. Characterization of Leber Congenital
Amaurosis-associated NMNAT1 Mutants. J. Biol. Chem. 2015, 290, 17228–17238. [CrossRef]
78. Koenekoop, R.K.; Wang, H.; Majewski, J.; Wang, X.; Lopez, I.; Ren, H.; Chen, Y.; Li, Y.; Fishman, G.A.;
Genead, M.; et al. Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease
pathway for retinal degeneration. Nat. Genet. 2012, 44, 1035–1039. [CrossRef]
79. Falk, M.J.; Zhang, Q.; Nakamaru-Ogiso, E.; Kannabiran, C.; Fonseca-Kelly, Z.; Chakarova, C.; Audo, I.;
Mackay, D.S.; Zeitz, C.; Borman, A.D.; et al. NMNAT1 mutations cause Leber congenital amaurosis. Nat. Genet.
2012, 44, 1040–1045. [CrossRef]
80. Lin, J.B.; Kubota, S.; Ban, N.; Yoshida, M.; Santeford, A.; Sene, A.; Nakamura, R.; Zapata, N.; Kubota, M.;
Tsubota, K.; et al. NAMPT-Mediated NAD+ Biosynthesis Is Essential for Vision In Mice. Cell Rep. 2016, 17,
69–85. [CrossRef]
81. Kuribayashi, H.; Baba, Y.; Iwagawa, T.; Arai, E.; Murakami, A.; Watanabe, S. Roles of Nmnat1 in the survival
of retinal progenitors through the regulation of pro-apoptotic gene expression via histone acetylation.
Cell Death Dis. 2018, 9, 891. [CrossRef]
82. Bai, S.; Sheline, C.T. NAD(+) maintenance attenuates light induced photoreceptor degeneration. Exp. Eye
Res. 2013, 108, 76–83. [CrossRef]
83. Sheline, C.T.; Zhou, Y.; Bai, S. Light-induced photoreceptor and RPE degeneration involve zinc toxicity and
are attenuated by pyruvate, nicotinamide, or cyclic light. Mol. Vis. 2010, 16, 2639–2652. [PubMed]
84. Fisher, C.R.; Ferrington, D.A. Perspective on AMD Pathobiology: A Bioenergetic Crisis in the RPE.
Investig. Ophthalmol. Vis. Sci. 2018, 59, AMD41–AMD47. [CrossRef] [PubMed]
85. Zhu, Y.; Zhao, K.-K.; Tong, Y.; Zhou, Y.-L.; Wang, Y.-X.; Zhao, P.-Q.; Wang, Z.-Y. Exogenous NAD+ decreases
oxidative stress and protects H2O2-treated RPE cells against necrotic death through the up-regulation of
autophagy. Sci. Rep. 2016, 6, 26322. [CrossRef] [PubMed]
86. Bergen, A.A. Nicotinamide, iRPE-in-a dish, and age-related macular degeneration therapy development.
Stem Cell Investig. 2017, 4, 81. [CrossRef]
87. Zabka, T.S.; Singh, J.; Dhawan, P.; Liederer, B.M.; Oeh, J.; Kauss, M.A.; Xiao, Y.; Zak, M.; Lin, T.; McCray, B.; et al.
Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase.
Toxicol. Sci. 2014, 144, 163–172. [CrossRef]
88. Zhao, G.; Green, C.F.; Hui, Y.-H.; Prieto, L.; Shepard, R.; Dong, S.; Wang, T.; Tan, B.; Gong, X.; Kays, L.; et al.
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal
Toxicity with Nicotinic Acid Coadministration. Mol. Cancer Ther. 2017, 16, 2677–2688. [CrossRef]
89. Sasaki, Y.; Araki, T.; Milbrandt, J. Stimulation of Nicotinamide Adenine Dinucleotide Biosynthetic Pathways
Delays Axonal Degeneration after Axotomy. J. Neurosci. 2006, 26, 8484–8491. [CrossRef]
90. Sasaki, Y.; Vohra, B.P.S.; Lund, F.E.; Milbrandt, J. Nicotinamide mononucleotide adenylyl transferase-mediated
axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine
dinucleotide. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29, 5525–5535. [CrossRef]
91. Mi, W.; Beirowski, B.; Gillingwater, T.H.; Adalbert, R.; Wagner, D.; Grumme, D.; Osaka, H.; Conforti, L.;
Arnhold, S.; Addicks, K.; et al. The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid
pathology in gracile axonal dystrophy mice. Brain 2005, 128, 405–416. [CrossRef]
92. Sasaki, Y.; Vohra, B.P.S.; Baloh, R.H.; Milbrandt, J. Transgenic mice expressing the Nmnat1 protein manifest
robust delay in axonal degeneration in vivo. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29, 6526–6534. [CrossRef]
Nutrients 2020, 12, 2871 16 of 21
93. Zhu, Y.; Zhang, L.; Sasaki, Y.; Milbrandt, J.; Gidday, J.M. Protection of Mouse Retinal Ganglion Cell
Axons and Soma from Glaucomatous and Ischemic Injury by Cytoplasmic Overexpression of Nmnat1.
Investig. Ophthalmol. Vis. Sci. 2013, 54, 25–36. [CrossRef] [PubMed]
94. Kitaoka, Y.; Munemasa, Y.; Kojima, K.; Hirano, A.; Ueno, S.; Takagi, H. Axonal protection by Nmnat3
overexpression with involvement of autophagy in optic nerve degeneration. Cell Death Dis. 2013, 4, e860.
[CrossRef] [PubMed]
95. Williams, P.A.; Harder, J.M.; Foxworth, N.E.; Cochran, K.E.; Philip, V.M.; Porciatti, V.; Smithies, O.; John, S.W.M.
Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 2017, 355,
756–760. [CrossRef]
96. Williams, P.A.; Harder, J.M.; Foxworth, N.E.; Cardozo, B.H.; Cochran, K.E.; John, S.W.M. Nicotinamide and
WLD(S) Act Together to Prevent Neurodegeneration in Glaucoma. Front. Neurosci. 2017, 11, 232. [CrossRef]
97. Williams, P.A.; Harder, J.M.; Cardozo, B.H.; Foxworth, N.E.; John, S.W.M. Nicotinamide treatment robustly
protects from inherited mouse glaucoma. Commun. Integr. Biol. 2018, 11, e1356956. [CrossRef] [PubMed]
98. Wen, Y.; Parrish, J.Z.; He, R.; Zhai, R.G.; Kim, M.D. Nmnat exerts neuroprotective effects in dendrites and
axons. Mol. Cell Neurosci. 2011, 48, 1–8. [CrossRef] [PubMed]
99. Weinreb, R.N.; Aung, T.; Medeiros, F.A. The pathophysiology and treatment of glaucoma: A review. JAMA
2014, 311, 1901–1911. [CrossRef]
100. Marshak, D.W. Retinal ganglion cells: Anatomy. In Encyclopedia of Neuroscience; Squire, L.R., Ed.; Academic
Press: Oxford, UK, 2009; pp. 211–218.
101. Feher, J. Quantitative Human Physiology; Academic press: Cambridge, MA, USA, 2012; pp. 456–470.
102. Weinreb, R.N.; Khaw, P.T. Primary open-angle glaucoma. Lancet 2004, 363, 1711–1720. [CrossRef]
103. Morgan, J.E. Retina ganglion cell degeneration in glaucoma: An opportunity missed? A review. Clin. Exp.
Ophthalmol. 2012, 40, 364–368. [CrossRef]
104. Whitmore, A.V.; Libby, R.T.; John, S.W.M. Glaucoma: Thinking in new ways—A rôle for autonomous axonal
self-destruction and other compartmentalised processes? Prog. Retin. Eye Res. 2005, 24, 639–662. [CrossRef]
105. Williams, P.A.; Howell, G.R.; Barbay, J.M.; Braine, C.E.; Sousa, G.L.; John, S.W.; Morgan, J.E. Retinal ganglion
cell dendritic atrophy in DBA/2J glaucoma. PLoS ONE 2013, 8, e72282. [CrossRef] [PubMed]
106. Morgan, J.E.; Tribble, J.; Fergusson, J.; White, N.; Erchova, I. The optical detection of retinal ganglion cell
damage. Eye 2017, 31, 199–205. [CrossRef] [PubMed]
107. Binley, K.E.; Ng, W.S.; Barde, Y.-A.; Song, B.; Morgan, J.E.; Kirik, D. Brain-derived neurotrophic factor
prevents dendritic retraction of adult mouse retinal ganglion cells. Eur. J. Neurosci. 2016, 44, 2028–2039.
[CrossRef] [PubMed]
108. Chong, R.S.; Martin, K.R. Retinal ganglion cell dendrites and glaucoma: A case of missing the wood for the
trees? Expert Rev. Ophthalmol. 2014, 9, 149–152. [CrossRef]
109. Zhou, L.; Chen, W.; Lin, D.; Hu, W.; Tang, Z. Neuronal apoptosis, axon damage and synapse loss occur
synchronously in acute ocular hypertension. Exp. Eye Res. 2019, 180, 77–85. [CrossRef]
110. Williams, P.A.; Tribble, J.R.; Pepper, K.W.; Cross, S.D.; Morgan, B.P.; Morgan, J.E.; John, S.W.; Howell, G.R.
Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic
degeneration in glaucoma. Mol. Neurodegener. 2016, 11, 26. [CrossRef]
111. Williams, P.A.; Morgan, J.E.; Votruba, M. Opa1 deficiency in a mouse model of dominant optic atrophy leads
to retinal ganglion cell dendropathy. Brain 2010, 133, 2942–2951. [CrossRef]
112. Williams, P.A.; Piechota, M.; von Ruhland, C.; Taylor, E.; Morgan, J.E.; Votruba, M. Opa1 is essential for
retinal ganglion cell synaptic architecture and connectivity. Brain 2012, 135, 493–505. [CrossRef]
113. Conforti, L.; Adalbert, R.; Coleman, M.P. Neuronal death: Where does the end begin? Trends Neurosci. 2007,
30, 159–166. [CrossRef]
114. Morgan, J.E. Optic nerve head structure in glaucoma: Astrocytes as mediators of axonal damage. Eye 2000,
14, 437–444. [CrossRef]
115. Vrabec, J.P.; Levin, L.A. The neurobiology of cell death in glaucoma. Eye 2007, 21 (Suppl S1), S11–S14.
[CrossRef] [PubMed]
116. Howell, G.R.; Libby, R.T.; Jakobs, T.C.; Smith, R.S.; Phalan, F.C.; Barter, J.W.; Barbay, J.M.; Marchant, J.K.;
Mahesh, N.; Porciatti, V.; et al. Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J
glaucoma. J. Cell Biol. 2007, 179, 1523–1537. [CrossRef] [PubMed]
Nutrients 2020, 12, 2871 17 of 21
117. Libby, R.T.; Anderson, M.G.; Pang, I.-H.; Robinson, Z.H.; Savinova, O.V.; Cosma, I.M.; Snow, A.M.Y.;
Wilson, L.A.; Smith, R.S.; Clark, A.F.; et al. Inherited glaucoma in DBA/2J mice: Pertinent disease features for
studying the neurodegeneration. Vis. Neurosci. 2005, 22, 637–648. [CrossRef] [PubMed]
118. Libby, R.T.; Li, Y.; Savinova, O.V.; Barter, J.; Smith, R.S.; Nickells, R.W.; John, S.W. Susceptibility to
neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet. 2005, 1, 17–26. [CrossRef]
[PubMed]
119. Qu, J.; Wang, D.; Grosskreutz, C.L. Mechanisms of retinal ganglion cell injury and defense in glaucoma.
Exp. Eye Res. 2010, 91, 48–53. [CrossRef] [PubMed]
120. Kong, G.Y.X.; Van Bergen, N.J.; Trounce, I.A.; Crowston, J.G. Mitochondrial Dysfunction and Glaucoma.
J. Glaucoma 2009, 18, 93–100. [CrossRef]
121. Levin, L.A.; Crowe, M.E.; Quigley, H.A.; The Lasker/IRRF Initiative on Astrocytes and Glaucomatous
Neurodegeneration Participants. Neuroprotection for glaucoma: Requirements for clinical translation.
Exp. Eye Res. 2017, 157, 34–37. [CrossRef]
122. Tamm, E.R.; Ethier, C.R.; Lasker, I.I.O.A.; Glaucomatous Neurodegeneration, P. Biological aspects of axonal
damage in glaucoma: A brief review. Exp. Eye Res. 2017, 157, 5–12. [CrossRef]
123. Pfeiffer, R.L.; Marc, R.E.; Jones, B.W. Persistent remodeling and neurodegeneration in late-stage retinal
degeneration. Prog. Retin. Eye Res. 2020, 74, 100771. [CrossRef]
124. Kamel, K.; Farrell, M.; O’Brien, C. Mitochondrial dysfunction in ocular disease: Focus on glaucoma.
Mitochondrion 2017, 35, 44–53. [CrossRef]
125. Carelli, V.; La Morgia, C.; Valentino, M.L.; Barboni, P.; Ross-Cisneros, F.N.; Sadun, A.A. Retinal ganglion
cell neurodegeneration in mitochondrial inherited disorders. Biochim. Biophys. Acta 2009, 1787, 518–528.
[CrossRef] [PubMed]
126. Osborne, N.N. Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma.
Exp. Eye Res. 2010, 90, 750–757. [CrossRef] [PubMed]
127. Green, D.R.; Galluzzi, L.; Kroemer, G. Cell biology. Metabolic control of cell death. Science 2014, 345, 1250256.
[CrossRef] [PubMed]
128. Alqawlaq, S.; Flanagan, J.G.; Sivak, J.M. All roads lead to glaucoma: Induced retinal injury cascades
contribute to a common neurodegenerative outcome. Exp. Eye Res. 2019, 183, 88–97. [CrossRef]
129. Tezel, G. TNF-α signaling in glaucomatous neurodegeneration. In Progress in Brain Research; Nucci, C.,
Cerulli, L., Osborne, N.N., Bagetta, G., Eds.; Elsevier: Amsterdam, The Netherlands, 2008; Volume 173,
pp. 409–421.
130. Johnson, E.C.; Guo, Y.; Cepurna, W.O.; Morrison, J.C. Neurotrophin roles in retinal ganglion cell survival:
Lessons from rat glaucoma models. Exp. Eye Res. 2009, 88, 808–815. [CrossRef]
131. Johnson, E.C.; Morrison, J.C. Friend or foe? Resolving the impact of glial responses in glaucoma. J. Glaucoma
2009, 18, 341–353. [CrossRef]
132. Eastlake, K.; Luis, J.; Limb, G.A. Potential of Müller Glia for Retina Neuroprotection. Curr. Eye Res. 2020, 45,
339–348. [CrossRef]
133. Seitz, R.; Ohlmann, A.; Tamm, E.R. The role of Müller glia and microglia in glaucoma. Cell Tissue Res. 2013,
353, 339–345. [CrossRef]
134. Lambiase, A.; Aloe, L.; Centofanti, M.; Parisi, V.; Mantelli, F.; Colafrancesco, V.; Manni, G.L.; Bucci, M.G.;
Bonini, S.; Levi-Montalcini, R. Experimental and clinical evidence of neuroprotection by nerve growth factor
eye drops: Implications for glaucoma. Proc. Natl. Acad. Sci. USA 2009, 106, 13469–13474. [CrossRef]
135. Di Polo, A.; Aigner, L.J.; Dunn, R.J.; Bray, G.M.; Aguayo, A.J. Prolonged delivery of brain-derived neurotrophic
factor by adenovirus-infected Müller cells temporarily rescues injured retinal ganglion cells. Proc. Natl. Acad.
Sci. USA 1998, 95, 3978–3983. [CrossRef]
136. Ji, J.-Z.; Elyaman, W.; Yip, H.K.; Lee, V.W.H.; Yick, L.-W.; Hugon, J.; So, K.-F. CNTF promotes survival of
retinal ganglion cells after induction of ocular hypertension in rats: The possible involvement of STAT3
pathway. Eur. J. Neurosci. 2004, 19, 265–272. [CrossRef] [PubMed]
137. Lindqvist, N.; Peinado-Ramónn, P.; Vidal-Sanz, M.; Hallböök, F. GDNF, Ret, GFRα1 and 2 in the adult rat
retino-tectal system after optic nerve transection. Exp. Neurol. 2004, 187, 487–499. [CrossRef] [PubMed]
138. Yang, Z.; Quigley, H.A.; Pease, M.E.; Yang, Y.; Qian, J.; Valenta, D.; Zack, D.J. Changes in Gene Expression in
Experimental Glaucoma and Optic Nerve Transection: The Equilibrium between Protective and Detrimental
Mechanisms. Investig. Ophthalmol. Vis. Sci. 2007, 48, 5539–5548. [CrossRef]
Nutrients 2020, 12, 2871 18 of 21
139. Maes, M.E.; Schlamp, C.L.; Nickells, R.W. BAX to basics: How the BCL2 gene family controls the death of
retinal ganglion cells. Prog. Retin. Eye Res. 2017, 57, 1–25. [CrossRef] [PubMed]
140. Tezel, G. Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences. Prog. Retin.
Eye Res. 2006, 25, 490–513. [CrossRef]
141. Attar, M.; Shen, J.; Ling, K.-H.J.; Tang-Liu, D. Ophthalmic drug delivery considerations at the cellular level:
Drug-metabolising enzymes and transporters. Expert Opin. Drug Deliv. 2005, 2, 891–908. [CrossRef]
142. Nocentini, A.; Supuran, C.T. Adrenergic agonists and antagonists as antiglaucoma agents: A literature and
patent review (2013–2019). Expert Opin. Ther. Pat. 2019, 29, 805–815. [CrossRef]
143. Berrino, E.; Supuran, C.T. Rho-kinase inhibitors in the management of glaucoma. Expert Opin. Ther. Pat.
2019, 29, 817–827. [CrossRef]
144. Naik, S.; Pandey, A.; Lewis, S.A.; Sadashiva, S.R.B.; Mutalik, S. Neuroprotection: A versatile approach to
combat glaucoma. Eur. J. Pharmacol. 2020, 881, 173208. [CrossRef]
145. Schwartz, K.; Budenz, D. Current management of glaucoma. Curr. Opin. Ophthalmol. 2004, 15, 119–126.
[CrossRef]
146. Conlon, R.; Saheb, H.; Ahmed, I.I.K. Glaucoma treatment trends: A review. Can. J. Ophthalmol. 2017, 52,
114–124. [CrossRef] [PubMed]
147. Ambati, J.; Fowler, B.J. Mechanisms of Age-Related Macular Degeneration. Neuron 2012, 75, 26–39. [CrossRef]
[PubMed]
148. Jager, R.D.; Mieler, W.F.; Miller, J.W. Age-Related Macular Degeneration. N. Engl. J. Med. 2008, 358, 2606–2617.
[CrossRef] [PubMed]
149. Ferris, F.L.; Wilkinson, C.P.; Bird, A.; Chakravarthy, U.; Chew, E.; Csaky, K.; Sadda, S.R. Clinical Classification
of Age-related Macular Degeneration. Ophthalmology 2013, 120, 844–851. [CrossRef]
150. Lamin, A.; Dubis, A.M.; Sivaprasad, S. Changes in macular drusen parameters preceding the development
of neovascular age-related macular degeneration. Eye 2019, 33, 910–916. [CrossRef]
151. Buschini, E.; Piras, A.; Nuzzi, R.; Vercelli, A. Age related macular degeneration and drusen:
Neuroinflammation in the retina. Prog. Neurobiol. 2011, 95, 14–25. [CrossRef]
152. Casson, R.J.; Chidlow, G.; Crowston, J.G.; Williams, P.A.; Wood, J.P.M. Retinal energy metabolism in health
and glaucoma. Prog. Retin. Eye Res. 2020, 100881. [CrossRef]
153. Jarrett, S.G.; Boulton, M.E. Consequences of oxidative stress in age-related macular degeneration. Mol. Asp.
Med. 2012, 33, 399–417. [CrossRef]
154. Pennesi, M.E.; Neuringer, M.; Courtney, R.J. Animal models of age related macular degeneration. Mol. Asp.
Med. 2012, 33, 487–509. [CrossRef]
155. Jones, M.; Mitchell, P.; Wang, J.J.; Sue, C. MELAS A3243G mitochondrial DNA mutation and age related
maculopathy. Am. J. Ophthalmol. 2004, 138, 1051–1053. [CrossRef]
156. Jones, M.M.; Manwaring, N.; Wang, J.J.; Rochtchina, E.; Mitchell, P.; Sue, C.M. Mitochondrial DNA
Haplogroups and Age-Related Maculopathy. Arch. Ophthalmol. 2007, 125, 1235–1240. [CrossRef] [PubMed]
157. Ebeling, M.C.; Polanco, J.R.; Qu, J.; Tu, C.; Montezuma, S.R.; Ferrington, D.A. Improving retinal mitochondrial
function as a treatment for age-related macular degeneration. Redox. Biol. 2020, 34, 101552. [CrossRef]
158. Kaarniranta, K.; Uusitalo, H.; Blasiak, J.; Felszeghy, S.; Kannan, R.; Kauppinen, A.; Salminen, A.;
Sinha, D.; Ferrington, D. Mechanisms of mitochondrial dysfunction and their impact on age-related
macular degeneration. Prog. Retin. Eye Res. 2020, 100858. [CrossRef] [PubMed]
159. Datta, S.; Cano, M.; Ebrahimi, K.; Wang, L.; Handa, J.T. The impact of oxidative stress and inflammation on
RPE degeneration in non-neovascular AMD. Prog. Retin. Eye Res. 2017, 60, 201–218. [CrossRef] [PubMed]
160. Ding, X.; Patel, M.; Chan, C.C. Molecular pathology of age-related macular degeneration. Prog. Retin. Eye Res.
2009, 28, 1–18. [CrossRef] [PubMed]
161. Tarallo, V.; Hirano, Y.; Gelfand, B.D.; Dridi, S.; Kerur, N.; Kim, Y.; Cho, W.G.; Kaneko, H.; Fowler, B.J.;
Bogdanovich, S.; et al. DICER1 Loss and Alu RNA Induce Age-Related Macular Degeneration via the NLRP3
Inflammasome and MyD88. Cell 2012, 149, 847–859. [CrossRef]
162. Liu, J.; Copland, D.A.; Theodoropoulou, S.; Chiu, H.A.A.; Barba, M.D.; Mak, K.W.; Mack, M.; Nicholson, L.B.;
Dick, A.D. Impairing autophagy in retinal pigment epithelium leads to inflammasome activation and
enhanced macrophage-mediated angiogenesis. Sci. Rep. 2016, 6, 20639. [CrossRef]
163. Luo, C.; Zhao, J.; Madden, A.; Chen, M.; Xu, H. Complement expression in retinal pigment epithelial cells is
modulated by activated macrophages. Exp. Eye Res. 2013, 112, 93–101. [CrossRef]
Nutrients 2020, 12, 2871 19 of 21
164. Vecino, E.; Rodriguez, F.D.; Ruzafa, N.; Pereiro, X.; Sharma, S.C. Glia–neuron interactions in the mammalian
retina. Prog. Retin. Eye Res. 2016, 51, 1–40. [CrossRef]
165. Sivaprasad, S.; Chong, N.V. The complement system and age-related macular degeneration. Eye 2006, 20,
867–872. [CrossRef]
166. Mammadzada, P.; Corredoira, P.M.; Andre, H. The role of hypoxia-inducible factors in neovascular age-related
macular degeneration: A gene therapy perspective. Cell Mol. Life Sci. 2020, 77, 819–833. [CrossRef] [PubMed]
167. Stefansson, E.; Geirsdottir, A.; Sigurdsson, H. Metabolic physiology in age related macular degeneration.
Prog. Retin. Eye Res. 2011, 30, 72–80. [CrossRef] [PubMed]
168. Smith, R.O.; Ninchoji, T.; Gordon, E.; André, H.; Dejana, E.; Vestweber, D.; Kvanta, A.; Claesson-Welsh, L.
Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. eLife 2020,
9, e54056. [CrossRef] [PubMed]
169. Arjamaa, O.; Nikinmaa, M.; Salminen, A.; Kaarniranta, K. Regulatory role of HIF-1alpha in the pathogenesis
of age-related macular degeneration (AMD). Ageing Res. Rev. 2009, 8, 349–358. [CrossRef]
170. Penn, J.S.; Madan, A.; Caldwell, R.B.; Bartoli, M.; Caldwell, R.W.; Hartnett, M.E. Vascular endothelial growth
factor in eye disease. Prog. Retin. Eye Res. 2008, 27, 331–371. [CrossRef]
171. Lin, M.; Hu, Y.; Chen, Y.; Zhou, K.K.; Jin, J.; Zhu, M.; Le, Y.-Z.; Ge, J.; Ma, J.-X. Impacts of Hypoxia-Inducible
Factor-1 Knockout in the Retinal Pigment Epithelium on Choroidal Neovascularization. Investig. Ophthalmol.
Vis. Sci. 2012, 53, 6197–6206. [CrossRef]
172. Andre, H.; Tunik, S.; Aronsson, M.; Kvanta, A. Hypoxia-Inducible Factor-1alpha Is Associated With Sprouting
Angiogenesis in the Murine Laser-Induced Choroidal Neovascularization Model. Investig. Ophthalmol.
Vis. Sci. 2015, 56, 6591–6604. [CrossRef]
173. Wang, H.; Geisen, P.; Wittchen, E.S.; King, B.; Burridge, K.; D’Amore, P.A.; Hartnett, M.E. The Role of RPE
Cell-Associated VEGF189 in Choroidal Endothelial Cell Transmigration across the RPE. Investig. Ophthalmol.
Vis. Sci. 2011, 52, 570–578. [CrossRef]
174. Zhao, W.; Wang, Y.-S.; Hui, Y.-N.; Zhu, J.; Zhang, P.; Li, X.; Dou, G.-R. Inhibition of proliferation, migration
and tube formation of choroidal microvascular endothelial cells by targeting HIF-1α with short hairpin
RNA-expressing plasmid DNA in human RPE cells in a coculture system. Graefe’s Arch. Clin. Exp. Ophthalmol.
2008, 246, 1413–1422. [CrossRef]
175. Hanus, J.; Anderson, C.; Wang, S. RPE necroptosis in response to oxidative stress and in AMD. Ageing Res.
Rev. 2015, 24, 286–298. [CrossRef]
176. Rozing, M.P.; Durhuus, J.A.; Krogh Nielsen, M.; Subhi, Y.; Kirkwood, T.B.; Westendorp, R.G.; Sorensen, T.L.
Age-related macular degeneration: A two-level model hypothesis. Prog. Retin. Eye Res. 2020, 76, 100825.
[CrossRef] [PubMed]
177. Cheng, S.Y.; Cipi, J.; Ma, S.; Hafler, B.P.; Kanadia, R.N.; Brush, R.S.; Agbaga, M.P.; Punzo, C. Altered
photoreceptor metabolism in mouse causes late stage age-related macular degeneration-like pathologies.
Proc. Natl. Acad. Sci. USA 2020, 117, 13094–13104. [CrossRef] [PubMed]
178. Leveillard, T.; Philp, N.J.; Sennlaub, F. Is Retinal Metabolic Dysfunction at the Center of the Pathogenesis of
Age-related Macular Degeneration? Int. J. Mol. Sci. 2019, 20, 762. [CrossRef] [PubMed]
179. Brown, D.M.; Kaiser, P.K.; Michels, M.; Soubrane, G.; Heier, J.S.; Kim, R.Y.; Sy, J.P.; Schneider, S. Ranibizumab
versus Verteporfin for Neovascular Age-Related Macular Degeneration. N. Engl. J. Med. 2006, 355, 1432–1444.
[CrossRef]
180. Rosenfeld, P.J.; Brown, D.M.; Heier, J.S.; Boyer, D.S.; Kaiser, P.K.; Chung, C.Y.; Kim, R.Y. Ranibizumab for
Neovascular Age-Related Macular Degeneration. N. Engl. J. Med. 2006, 355, 1419–1431. [CrossRef]
181. Mantel, I. Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration:
From Clinical Trials to Real-Life Requirements. Transl. Vis. Sci. Technol. 2015, 4, 6. [CrossRef]
182. Costa, R.A.; Jorge, R.; Calucci, D.; Melo, L.A.S.; Cardillo, J.A.; Scott, I.U. Intravitreal bevacizumab (Avastin)
in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with
age-related macular degeneration (IBeVe Study). Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245, 1273–1280.
[CrossRef]
183. Kaiser, P.K. Verteporfin photodynamic therapy and anti-angiogenic drugs: Potential for combination therapy
in exudative age-related macular degeneration. Curr. Med. Res. Opin. 2007, 23, 477–487. [CrossRef]
Nutrients 2020, 12, 2871 20 of 21
184. Jaffe, G.J.; Eliott, D.; Wells, J.A.; Prenner, J.L.; Papp, A.; Patel, S. A Phase 1 Study of Intravitreous E10030 in
Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology 2016,
123, 78–85. [CrossRef]
185. Kertes, P.J. Massive Peripapillary Subretinal Neovascularization: An Indication for Submacular Surgery.
Retina 2004, 24, 219–225. [CrossRef]
186. Giansanti, F.; Eandi, C.M.; Virgili, G. Submacular surgery for choroidal neovascularisation secondary to
age-related macular degeneration. Cochrane Database Syst. Rev. 2009. [CrossRef] [PubMed]
187. Rhoades, W.; Dickson, D.; Do, D.V. Potential role of lampalizumab for treatment of geographic atrophy.
Clin. Ophthalmol. 2015, 9, 1049–1056. [CrossRef] [PubMed]
188. Holz, F.G.; Sadda, S.R.; Busbee, B.; Chew, E.Y.; Mitchell, P.; Tufail, A.; Brittain, C.; Ferrara, D.; Gray, S.;
Honigberg, L.; et al. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related
Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol. 2018,
136, 666–677. [CrossRef] [PubMed]
189. Yates, P.A.; Holbrook, K.; Reichel, E.; Waheed, N.K.; Patrie, J.; Investigators, T. Designing a Clinical Study to
Evaluate Potential Therapeutics for Geographic Atrophy Secondary to Non-Exudative Age-Related Macular
Degeneration. Investig. Ophthalmol. Vis. Sci. 2015, 56, 2835.
190. Di Caprio, R.; Lembo, S.; Di Costanzo, L.; Balato, A.; Monfrecola, G. Anti-Inflammatory Properties of Low
and High Doxycycline Doses: An In Vitro Study. Mediat. Inflamm. 2015, 2015, 329418. [CrossRef]
191. Schwartz, S.D.; Regillo, C.D.; Lam, B.L.; Eliott, D.; Rosenfeld, P.J.; Gregori, N.Z.; Hubschman, J.-P.; Davis, J.L.;
Heilwell, G.; Spirn, M.; et al. Human embryonic stem cell-derived retinal pigment epithelium in patients
with age-related macular degeneration and Stargardt’s macular dystrophy: Follow-up of two open-label
phase 1/2 studies. Lancet 2015, 385, 509–516. [CrossRef]
192. Lin, J.B.; Apte, R.S. NAD(+) and sirtuins in retinal degenerative diseases: A look at future therapies.
Prog. Retin. Eye Res. 2018, 67, 118–129. [CrossRef]
193. Syc-Mazurek, S.B.; Libby, R.T. Axon injury signaling and compartmentalized injury response in glaucoma.
Prog. Retin. Eye Res. 2019, 73, 100769. [CrossRef]
194. Kouassi Nzoughet, J.; Chao de la Barca, J.M.; Guehlouz, K.; Leruez, S.; Coulbault, L.; Allouche, S.; Bocca, C.;
Muller, J.; Amati-Bonneau, P.; Gohier, P.; et al. Nicotinamide Deficiency in Primary Open-Angle Glaucoma.
Invest. Ophthalmol. Vis. Sci. 2019, 60, 2509–2514. [CrossRef]
195. Hui, F.; Tang, J.; Williams, P.A.; McGuinness, M.B.; Hadoux, X.; Casson, R.J.; Coote, M.; Trounce, I.A.;
Martin, K.R.; van Wijngaarden, P.; et al. Improvement in inner retinal function in glaucoma with nicotinamide
(vitamin B3) supplementation: A crossover randomized clinical trial. Clin. Exp. Ophthalmol. 2020. [CrossRef]
196. McElnea, E.M.; Quill, B.; Docherty, N.; Wallace, D.M.; Irnaten, M.; Farrell, M.; O’Brien, C. Lipofuscin
Accumulation and Autophagy in Human Lamina Cribrosa Cells. Investig. Ophthalmol. Vis. Sci. 2011, 52, 2677.
[CrossRef] [PubMed]
197. Zhang, D.-X.; Zhang, J.-P.; Hu, J.-Y.; Huang, Y.-S. The potential regulatory roles of NAD+ and its metabolism
in autophagy. Metab. Clin. Exp. 2016, 65, 454–462. [CrossRef] [PubMed]
198. Sedlackova, L.; Otten, E.G.; Scialo, F.; Shapira, D.; Kataura, T.; Carroll, B.; Seranova, E.; Rabanal-Ruiz, Y.;
Kelly, G.; Stefanatos, R.; et al. Autophagy promotes cell and organismal survival by maintaining NAD(H)
pools. bioRxiv 2020. [CrossRef]
199. Luo, H.; Zhou, M.; Ji, K.; Zhuang, J.; Dang, W.; Fu, S.; Sun, T.; Zhang, X. Expression of Sirtuins in the Retinal
Neurons of Mice, Rats, and Humans. Front. Aging Neurosci. 2017, 9, 366. [CrossRef]
200. Mimura, T.; Kaji, Y.; Noma, H.; Funatsu, H.; Okamoto, S. The role of SIRT1 in ocular aging. Exp. Eye Res.
2013, 116, 17–26. [CrossRef]
201. Ji, D.; Li, G.Y.; Osborne, N.N. Nicotinamide attenuates retinal ischemia and light insults to neurones.
Neurochem. Int. 2008, 52, 786–798. [CrossRef]
202. Aman, Y.; Frank, J.; Lautrup, S.H.; Matysek, A.; Niu, Z.; Yang, G.; Shi, L.; Bergersen, L.H.; Storm-Mathisen, J.;
Rasmussen, L.J.; et al. The NAD(+)-mitophagy axis in healthy longevity and in artificial intelligence-based
clinical applications. Mech. Ageing Dev. 2020, 185, 111194. [CrossRef]
203. Hyttinen, J.M.T.; Viiri, J.; Kaarniranta, K.; Blasiak, J. Mitochondrial quality control in AMD: Does mitophagy
play a pivotal role? Cell Mol. Life Sci. 2018, 75, 2991–3008. [CrossRef]
204. Westenskow, P.D. Nicotinamide: A novel treatment for age-related macular degeneration? Stem. Cell Investig.
2017, 4, 86. [CrossRef]
Nutrients 2020, 12, 2871 21 of 21
205. Sridevi Gurubaran, I.; Viiri, J.; Koskela, A.; Hyttinen, J.M.T.; Paterno, J.J.; Kis, G.; Antal, M.; Urtti, A.;
Kauppinen, A.; Felszeghy, S.; et al. Mitophagy in the Retinal Pigment Epithelium of Dry Age-Related
Macular Degeneration Investigated in the NFE2L2/PGC-1alpha(-/-) Mouse Model. Int. J. Mol. Sci. 2020,
21, 1976. [CrossRef]
206. Felszeghy, S.; Viiri, J.; Paterno, J.J.; Hyttinen, J.M.T.; Koskela, A.; Chen, M.; Leinonen, H.; Tanila, H.;
Kivinen, N.; Koistinen, A.; et al. Loss of NRF-2 and PGC-1alpha genes leads to retinal pigment epithelium
damage resembling dry age-related macular degeneration. Redox. Biol. 2019, 20, 1–12. [CrossRef] [PubMed]
207. Fang, E.F.; Kassahun, H.; Croteau, D.L.; Scheibye-Knudsen, M.; Marosi, K.; Lu, H.; Shamanna, R.A.;
Kalyanasundaram, S.; Bollineni, R.C.; Wilson, M.A.; et al. NAD(+) Replenishment Improves Lifespan and
Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair. Cell Metab. 2016, 24, 566–581.
[CrossRef] [PubMed]
208. Fang, E.F.; Bohr, V.A. NAD(+): The convergence of DNA repair and mitophagy. Autophagy 2017, 13, 442–443.
[CrossRef]
209. Fang, E.F.; Hou, Y.; Lautrup, S.; Jensen, M.B.; Yang, B.; SenGupta, T.; Caponio, D.; Khezri, R.; Demarest, T.G.;
Aman, Y.; et al. NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome.
Nat. Commun. 2019, 10, 5284. [CrossRef] [PubMed]
210. Saini, J.S.; Corneo, B.; Miller, J.D.; Kiehl, T.R.; Wang, Q.; Boles, N.C.; Blenkinsop, T.A.; Stern, J.H.; Temple, S.
Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration.
Cell Stem Cell 2017, 20, 635–647. [CrossRef]
211. Zhou, M.; Geathers, J.S.; Grillo, S.L.; Weber, S.R.; Wang, W.; Zhao, Y.; Sundstrom, J.M. Role of
Epithelial-Mesenchymal Transition in Retinal Pigment Epithelium Dysfunction. Front. Cell Dev. Biol.
2020, 8, 501. [CrossRef]
212. Hyttinen, J.M.T.; Kannan, R.; Felszeghy, S.; Niittykoski, M.; Salminen, A.; Kaarniranta, K. The Regulation of
NFE2L2 (NRF2) Signalling and Epithelial-to-Mesenchymal Transition in Age-Related Macular Degeneration
Pathology. Int. J. Mol. Sci. 2019, 20, 5800. [CrossRef]
213. Poljsak, B.; Milisav, I. Vitamin B3 forms as precursors to NAD+: Are they safe? Trends Food Sci. Technol. 2018,
79, 198–203. [CrossRef]
214. Knip, M.; Douek, I.F.; Moore, W.P.T.; Gillmor, H.A.; McLean, A.E.M.; Bingley, P.J.; Gale, E.A.M.; ENDIT
Group. Safety of high-dose nicotinamide: A review. Diabetologia 2000, 43, 1337–1345. [CrossRef]
215. Conze, D.; Brenner, C.; Kruger, C.L. Safety and Metabolism of Long-term Administration of NIAGEN
(Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of
Healthy Overweight Adults. Sci. Rep. 2019, 9, 9772. [CrossRef]
216. Martens, C.R.; Denman, B.A.; Mazzo, M.R.; Armstrong, M.L.; Reisdorph, N.; McQueen, M.B.; Chonchol, M.;
Seals, D.R. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy
middle-aged and older adults. Nat. Commun. 2018, 9, 1286. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
